Destiny Pharma to present at Shares & AJ Bell Webinar – 6th July 2021
News
Tuesday June 29, 2021
Destiny Pharma to present at Shares & AJ Bell Webinar – 6th July 2021
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma to present at the Shares and AJ Bell Investor Webinar on 06 July 2021 Brighton, United Kingdom – 29 June […]
Thursday June 10, 2021
XF-73 data abstract to be presented at 2021 ECCMID
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress XF-73 […]
Monday June 7, 2021
Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance Highlights the global threat of the “silent pandemic” and the urgent need for the […]
Friday June 4, 2021
Result of Annual General Meeting
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Result of Annual General Meeting Brighton, United Kingdom – 3rd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company […]
Wednesday June 2, 2021
Positive update on microbiome therapeutic NTCD-M3
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections · Preparations for Phase 3 study progressing to plan · Established […]